{"id": "article-20133_0", "title": "Crohn Disease -- Continuing Education Activity", "content": "Crohn disease and ulcerative colitis are distinct clinical entities collectively referred to as \"inflammatory bowel disease\" (IBD). These gastrointestinal conditions have an unclear etiology, although genetic, environmental, and immunologic influences have been implicated. Crohn disease can affect any part of the digestive tract but most commonly involves the small intestine and proximal colon. Gastrointestinal symptoms are prominent, though extraintestinal pathology and systemic inflammation can also arise. Patients may initially present with nonspecific symptoms, and some may not have a clear family history. Thus, diagnostic and treatment delays are not uncommon. Understanding the condition's pathophysiology and evidenced-based management strategies can improve patient outcomes.", "contents": "Crohn Disease -- Continuing Education Activity. Crohn disease and ulcerative colitis are distinct clinical entities collectively referred to as \"inflammatory bowel disease\" (IBD). These gastrointestinal conditions have an unclear etiology, although genetic, environmental, and immunologic influences have been implicated. Crohn disease can affect any part of the digestive tract but most commonly involves the small intestine and proximal colon. Gastrointestinal symptoms are prominent, though extraintestinal pathology and systemic inflammation can also arise. Patients may initially present with nonspecific symptoms, and some may not have a clear family history. Thus, diagnostic and treatment delays are not uncommon. Understanding the condition's pathophysiology and evidenced-based management strategies can improve patient outcomes."}
{"id": "article-20133_1", "title": "Crohn Disease -- Continuing Education Activity", "content": "This activity for healthcare workers is designed to enhance learners' competence in evaluating and managing Crohn disease. This activity is also designed to equip learners with valuable insights to collaborate effectively with an interprofessional team caring for individuals with this condition.", "contents": "Crohn Disease -- Continuing Education Activity. This activity for healthcare workers is designed to enhance learners' competence in evaluating and managing Crohn disease. This activity is also designed to equip learners with valuable insights to collaborate effectively with an interprofessional team caring for individuals with this condition."}
{"id": "article-20133_2", "title": "Crohn Disease -- Continuing Education Activity", "content": "Objectives: Identify the signs and symptoms indicative of Crohn disease. Create a clinically sound diagnostic\u00a0strategy to evaluate a patient suspected to have Crohn disease. Differentiate the various Crohn disease treatment options\u00a0to develop a personalized management plan for an individual diagnosed with this condition. Collaborate effectively with an interprofessional team to formulate short- and long-term care plans for patients with Crohn disease. Access free multiple choice questions on this topic.", "contents": "Crohn Disease -- Continuing Education Activity. Objectives: Identify the signs and symptoms indicative of Crohn disease. Create a clinically sound diagnostic\u00a0strategy to evaluate a patient suspected to have Crohn disease. Differentiate the various Crohn disease treatment options\u00a0to develop a personalized management plan for an individual diagnosed with this condition. Collaborate effectively with an interprofessional team to formulate short- and long-term care plans for patients with Crohn disease. Access free multiple choice questions on this topic."}
{"id": "article-20133_3", "title": "Crohn Disease -- Introduction", "content": "Crohn disease is a form of inflammatory bowel disease (IBD) like\u00a0ulcerative colitis,\u00a0though Crohn disease often presents more subtly. Crohn disease is an immunologically mediated inflammatory gastrointestinal condition, with pathology involving the entire thickness of the bowel wall.", "contents": "Crohn Disease -- Introduction. Crohn disease is a form of inflammatory bowel disease (IBD) like\u00a0ulcerative colitis,\u00a0though Crohn disease often presents more subtly. Crohn disease is an immunologically mediated inflammatory gastrointestinal condition, with pathology involving the entire thickness of the bowel wall."}
{"id": "article-20133_4", "title": "Crohn Disease -- Introduction", "content": "The condition may involve any part of the gastrointestinal tract. Minnesota data show that 19% of patients present with stricturing or fistulizing disease within 90 days of diagnosis. About half of all patients experience an intestinal complication, such as fistulae, phlegmons, strictures, and abscesses, within 20 years of diagnosis. Population-based studies from Northern Europe and Minnesota suggest that Crohn disease presents with ileal, ileocolonic, or colonic involvement each third of the time, with disease migration occurring in only 6% to 14% of patients. [1] Pathology in the upper gastrointestinal tract, ileal, or ileocolonic region portends a greater stricturing and fistulizing risk compared to colonic involvement. [2] Crohn disease may also have extraintestinal manifestations, which often involve the eyes, skin, liver, and joints.", "contents": "Crohn Disease -- Introduction. The condition may involve any part of the gastrointestinal tract. Minnesota data show that 19% of patients present with stricturing or fistulizing disease within 90 days of diagnosis. About half of all patients experience an intestinal complication, such as fistulae, phlegmons, strictures, and abscesses, within 20 years of diagnosis. Population-based studies from Northern Europe and Minnesota suggest that Crohn disease presents with ileal, ileocolonic, or colonic involvement each third of the time, with disease migration occurring in only 6% to 14% of patients. [1] Pathology in the upper gastrointestinal tract, ileal, or ileocolonic region portends a greater stricturing and fistulizing risk compared to colonic involvement. [2] Crohn disease may also have extraintestinal manifestations, which often involve the eyes, skin, liver, and joints."}
{"id": "article-20133_5", "title": "Crohn Disease -- Introduction", "content": "The disease runs a chronic and often progressive course. Frequent symptoms include diarrhea, abdominal pain, nausea, or vomiting. Weight loss, fever, and fatigue are systemic manifestations of this condition. Without treatment, longstanding inflammation can produce debilitating complications. Early diagnosis and management can help\u00a0optimize quality of life and outcomes for patients with Crohn disease. [3] [4] [5] [6] [7]", "contents": "Crohn Disease -- Introduction. The disease runs a chronic and often progressive course. Frequent symptoms include diarrhea, abdominal pain, nausea, or vomiting. Weight loss, fever, and fatigue are systemic manifestations of this condition. Without treatment, longstanding inflammation can produce debilitating complications. Early diagnosis and management can help\u00a0optimize quality of life and outcomes for patients with Crohn disease. [3] [4] [5] [6] [7]"}
{"id": "article-20133_6", "title": "Crohn Disease -- Etiology", "content": "IBD's exact etiology is unknown. However, substantial evidence suggests that the\u00a0condition may result from an inappropriate immune response to environmental antigens like\u00a0drugs, toxins, infections, or intestinal microbes in a genetically susceptible host. Large-scale genome studies have identified over\u00a0200 IBD-associated genes and more than 71 Crohn disease\u2013susceptibility loci. [8] [9] [10]", "contents": "Crohn Disease -- Etiology. IBD's exact etiology is unknown. However, substantial evidence suggests that the\u00a0condition may result from an inappropriate immune response to environmental antigens like\u00a0drugs, toxins, infections, or intestinal microbes in a genetically susceptible host. Large-scale genome studies have identified over\u00a0200 IBD-associated genes and more than 71 Crohn disease\u2013susceptibility loci. [8] [9] [10]"}
{"id": "article-20133_7", "title": "Crohn Disease -- Etiology", "content": "Genetic variants are associated with certain Crohn disease phenotypes. For example, NOD2/CARD15 mutations have been detected in patients with Crohn disease presenting with ileal involvement and increased severity at a younger age. These individuals often require surgical intervention. Genotyping is expected\u00a0to provide prognostic information on\u00a0disease severity\u00a0in the future.\u00a0Currently, genetic testing remains\u00a0mostly a research tool. [11]", "contents": "Crohn Disease -- Etiology. Genetic variants are associated with certain Crohn disease phenotypes. For example, NOD2/CARD15 mutations have been detected in patients with Crohn disease presenting with ileal involvement and increased severity at a younger age. These individuals often require surgical intervention. Genotyping is expected\u00a0to provide prognostic information on\u00a0disease severity\u00a0in the future.\u00a0Currently, genetic testing remains\u00a0mostly a research tool. [11]"}
{"id": "article-20133_8", "title": "Crohn Disease -- Epidemiology", "content": "Crohn disease is most commonly seen in North America, Northern Europe, and New Zealand. The condition has a bimodal distribution, with the onset occurring most frequently between ages 15 and 30 and 40 and 60. Crohn disease is more prominent in urban than rural areas. The condition has a high incidence in Northern Europeans and people of Jewish descent (incidence 3.2 per 1000 individuals). Prevalence in Asians, Africans, and South Americans is low. [12] However, recent studies have shown a significant increase in incidence in rapidly industrializing areas of Asia, Africa, and Australasia. [13]", "contents": "Crohn Disease -- Epidemiology. Crohn disease is most commonly seen in North America, Northern Europe, and New Zealand. The condition has a bimodal distribution, with the onset occurring most frequently between ages 15 and 30 and 40 and 60. Crohn disease is more prominent in urban than rural areas. The condition has a high incidence in Northern Europeans and people of Jewish descent (incidence 3.2 per 1000 individuals). Prevalence in Asians, Africans, and South Americans is low. [12] However, recent studies have shown a significant increase in incidence in rapidly industrializing areas of Asia, Africa, and Australasia. [13]"}
{"id": "article-20133_9", "title": "Crohn Disease -- Pathophysiology", "content": "Crohn disease is multifactorial. Genetic, infectious, immunological, environmental, and dietary factors contribute to the condition's development. The excessive immune response arises from innate and acquired mechanisms involving intestinal macrophages, neutrophils, and helper T-cells (T h ), promoting proinflammatory mediators like tumor necrosis factor-\u03b1 (TNF-\u03b1). T h 1 and T h 17 are crucial mediators in the Crohn disease inflammatory cascade. Colonic Crohn lesions were found to have high levels of cytokines like interferon-\u03b3 and interleukins (ILs) 2, 12, and 18. [14] [15] [16]", "contents": "Crohn Disease -- Pathophysiology. Crohn disease is multifactorial. Genetic, infectious, immunological, environmental, and dietary factors contribute to the condition's development. The excessive immune response arises from innate and acquired mechanisms involving intestinal macrophages, neutrophils, and helper T-cells (T h ), promoting proinflammatory mediators like tumor necrosis factor-\u03b1 (TNF-\u03b1). T h 1 and T h 17 are crucial mediators in the Crohn disease inflammatory cascade. Colonic Crohn lesions were found to have high levels of cytokines like interferon-\u03b3 and interleukins (ILs) 2, 12, and 18. [14] [15] [16]"}
{"id": "article-20133_10", "title": "Crohn Disease -- Pathophysiology", "content": "Inflammation in the initial stages of the illness gives rise to nonspecific symptoms such as fever and malaise. Diarrhea and abdominal pain arise from intestinal injury. Right lower quadrant (RLQ) pain may\u00a0manifest\u00a0due to ileocecal involvement. Terminal ileal damage can give rise to malabsorption and vitamin deficiencies. Anemia can arise from\u00a0either vitamin B12\u00a0insufficiency\u00a0or fecal blood loss, depending on which intestinal area is most involved. Extraction of inflammation\u00a0can cause dysfunction of the surrounding organs\u00a0due to fistulae formation.", "contents": "Crohn Disease -- Pathophysiology. Inflammation in the initial stages of the illness gives rise to nonspecific symptoms such as fever and malaise. Diarrhea and abdominal pain arise from intestinal injury. Right lower quadrant (RLQ) pain may\u00a0manifest\u00a0due to ileocecal involvement. Terminal ileal damage can give rise to malabsorption and vitamin deficiencies. Anemia can arise from\u00a0either vitamin B12\u00a0insufficiency\u00a0or fecal blood loss, depending on which intestinal area is most involved. Extraction of inflammation\u00a0can cause dysfunction of the surrounding organs\u00a0due to fistulae formation."}
{"id": "article-20133_11", "title": "Crohn Disease -- Pathophysiology", "content": "Extraintestinal manifestations of Crohn disease are mostly due to systemic inflammation and include arthritis, uveitis, pericholangitis, and renal disorders. These conditions may appear before the intestinal manifestations. Systemic amyloidosis is a rare, late sequela.", "contents": "Crohn Disease -- Pathophysiology. Extraintestinal manifestations of Crohn disease are mostly due to systemic inflammation and include arthritis, uveitis, pericholangitis, and renal disorders. These conditions may appear before the intestinal manifestations. Systemic amyloidosis is a rare, late sequela."}
{"id": "article-20133_12", "title": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines", "content": "The small and large intestines comprise most of the gastrointestinal tract. The mucosal surfaces in these gut regions are designed for maximal absorption\u2014of nutrients in the small bowel and water in the large bowel. Thus, more environmental antigens can enter the bloodstream through the gut than the skin and pulmonary tract.", "contents": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines. The small and large intestines comprise most of the gastrointestinal tract. The mucosal surfaces in these gut regions are designed for maximal absorption\u2014of nutrients in the small bowel and water in the large bowel. Thus, more environmental antigens can enter the bloodstream through the gut than the skin and pulmonary tract."}
{"id": "article-20133_13", "title": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines", "content": "The small intestine is typically 6 meters long and divided into the duodenum, jejunum, and ileum. The duodenum is retroperitoneal, while the jejunum and ileum are intraperitoneal. The ileum terminates in the ileocecal valve.", "contents": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines. The small intestine is typically 6 meters long and divided into the duodenum, jejunum, and ileum. The duodenum is retroperitoneal, while the jejunum and ileum are intraperitoneal. The ileum terminates in the ileocecal valve."}
{"id": "article-20133_14", "title": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines", "content": "The mucosal surface of the small bowel consists of columnar absorptive epithelium and goblet, endocrine, and Paneth cells. Columnar cells occupying most of the small intestinal mucosa have numerous villi for absorbing nutrients. Under the microscope, these villi resemble a brush. Thus, this part of the small bowel luminal surface is called the \"brush border.\" Each villus' core\u00a0houses\u00a0a portion of the lamina propria, which contains blood and lymph vessels, leukocytes, fibroblasts, and smooth muscle cells. The crypts of Lieberkuhn (or simply \"crypts\") are the furrows between the villi's bases extending as deep as the muscularis mucosa. The normal villus-to-crypt height is 4 to 5.1:1.", "contents": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines. The mucosal surface of the small bowel consists of columnar absorptive epithelium and goblet, endocrine, and Paneth cells. Columnar cells occupying most of the small intestinal mucosa have numerous villi for absorbing nutrients. Under the microscope, these villi resemble a brush. Thus, this part of the small bowel luminal surface is called the \"brush border.\" Each villus' core\u00a0houses\u00a0a portion of the lamina propria, which contains blood and lymph vessels, leukocytes, fibroblasts, and smooth muscle cells. The crypts of Lieberkuhn (or simply \"crypts\") are the furrows between the villi's bases extending as deep as the muscularis mucosa. The normal villus-to-crypt height is 4 to 5.1:1."}
{"id": "article-20133_15", "title": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines", "content": "Goblet, endocrine, and Paneth cells are scattered between the columnar cells and may be found in the crypts. Goblet cells secrete mucin for gut protection and lubrication. Gut endocrine cells secrete various peptides that regulate the digestive process. Paneth cells produce antimicrobial proteins like defensins. The crypts also contain stem cells, which replace damaged or sloughing luminal cells. In the duodenum, the submucosa contains Brenner glands. These glands secrete mucus, bicarbonate, glycoproteins, and pepsinogen II. Microscopically, Brenner glands resemble pyloric mucous glands.", "contents": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines. Goblet, endocrine, and Paneth cells are scattered between the columnar cells and may be found in the crypts. Goblet cells secrete mucin for gut protection and lubrication. Gut endocrine cells secrete various peptides that regulate the digestive process. Paneth cells produce antimicrobial proteins like defensins. The crypts also contain stem cells, which replace damaged or sloughing luminal cells. In the duodenum, the submucosa contains Brenner glands. These glands secrete mucus, bicarbonate, glycoproteins, and pepsinogen II. Microscopically, Brenner glands resemble pyloric mucous glands."}
{"id": "article-20133_16", "title": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines", "content": "The muscularis mucosa contains smooth muscle sheets anchoring the absorptive villi and crypts. The smooth muscle cells in this area facilitate villous folding and unfolding to maximize the gut absorptive surface.", "contents": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines. The muscularis mucosa contains smooth muscle sheets anchoring the absorptive villi and crypts. The smooth muscle cells in this area facilitate villous folding and unfolding to maximize the gut absorptive surface."}
{"id": "article-20133_17", "title": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines", "content": "The large intestine (colon) is normally about 1.5 meters long and comprises the cecum and the ascending, transverse, and descending colon. The sigmoid colon extends from the pelvic brim, traverses within the peritoneum, and becomes the rectum at the S3 vertebral level. The distal rectum is extraperitoneal.", "contents": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines. The large intestine (colon) is normally about 1.5 meters long and comprises the cecum and the ascending, transverse, and descending colon. The sigmoid colon extends from the pelvic brim, traverses within the peritoneum, and becomes the rectum at the S3 vertebral level. The distal rectum is extraperitoneal."}
{"id": "article-20133_18", "title": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines", "content": "The colon's mucosal surface is lined mainly by columnar absorptive cells with shorter villi than small intestinal epithelial cells. The colonic crypts also contain goblet, endocrine, Paneth, and stem cells.", "contents": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines. The colon's mucosal surface is lined mainly by columnar absorptive cells with shorter villi than small intestinal epithelial cells. The colonic crypts also contain goblet, endocrine, Paneth, and stem cells."}
{"id": "article-20133_19", "title": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines", "content": "Both small and large intestinal mucosae have great regenerative capacities, with complete cell turnover occurring within a week. Thus, these gut segments have remarkable reparative abilities but are also prone to cytotoxic damage from cancer therapies.", "contents": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines. Both small and large intestinal mucosae have great regenerative capacities, with complete cell turnover occurring within a week. Thus, these gut segments have remarkable reparative abilities but are also prone to cytotoxic damage from cancer therapies."}
{"id": "article-20133_20", "title": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines", "content": "Bacteria colonize the small and large bowel mucosae. Colonization is highest at the ileum. Nonpathogenic gram-negative bacterial strains, eg, nonpathogenic E coli , typically comprise the intestinal flora.", "contents": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines. Bacteria colonize the small and large bowel mucosae. Colonization is highest at the ileum. Nonpathogenic gram-negative bacterial strains, eg, nonpathogenic E coli , typically comprise the intestinal flora."}
{"id": "article-20133_21", "title": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines", "content": "Mucosal and submucosal lymphoid tissue nodules are scattered throughout the intestines. In the ileum, these nodules form the Peyer patches. M cells in the surface epithelium covering the lymph nodules can engulf antigens intact from the intestinal lumen to the antigen-presenting cells beneath the mucosal surface. Antigen-presenting cells consist of macrophages and dendritic cells. T lymphocytes, activated B cells, and plasma cells are scattered in the lamina propria. Immunoglobulins are also scattered in the lamina propria, but the most abundant is immunoglobulin A.", "contents": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines. Mucosal and submucosal lymphoid tissue nodules are scattered throughout the intestines. In the ileum, these nodules form the Peyer patches. M cells in the surface epithelium covering the lymph nodules can engulf antigens intact from the intestinal lumen to the antigen-presenting cells beneath the mucosal surface. Antigen-presenting cells consist of macrophages and dendritic cells. T lymphocytes, activated B cells, and plasma cells are scattered in the lamina propria. Immunoglobulins are also scattered in the lamina propria, but the most abundant is immunoglobulin A."}
{"id": "article-20133_22", "title": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines", "content": "The outer muscular layers of the intestines are responsible for peristalsis. The myenteric plexus regulates movements in these layers. The serosal layer consists primarily of collagen and elastic fibers. A layer of mesothelial cells covers the serosa, secreting a serous fluid that lubricates the outer intestinal surfaces\u00a0(see Image . Large Intestine Transverse Section).", "contents": "Crohn Disease -- Pathophysiology -- Anatomy of the Small and Large Intestines. The outer muscular layers of the intestines are responsible for peristalsis. The myenteric plexus regulates movements in these layers. The serosal layer consists primarily of collagen and elastic fibers. A layer of mesothelial cells covers the serosa, secreting a serous fluid that lubricates the outer intestinal surfaces\u00a0(see Image . Large Intestine Transverse Section)."}
{"id": "article-20133_23", "title": "Crohn Disease -- Histopathology", "content": "Crohn disease's\u00a0characteristic transmural inflammation can\u00a0occur in the entire\u00a0gastrointestinal tract from the mouth to the perianal area. However, the condition most frequently\u00a0affects the terminal ileum and right colon.", "contents": "Crohn Disease -- Histopathology. Crohn disease's\u00a0characteristic transmural inflammation can\u00a0occur in the entire\u00a0gastrointestinal tract from the mouth to the perianal area. However, the condition most frequently\u00a0affects the terminal ileum and right colon."}
{"id": "article-20133_24", "title": "Crohn Disease -- Histopathology", "content": "The initial lesion starts as an infiltrate around an intestinal crypt. Ulceration then develops,\u00a0initially involving only\u00a0the superficial mucosa but later growing into the deeper layers. Noncaseating granulomas develop with continuing inflammation, spreading toward the intestinal wall. Granuloma formation is seen in up to 33% of patients with Crohn disease,\u00a0but their absence does not exclude the diagnosis.", "contents": "Crohn Disease -- Histopathology. The initial lesion starts as an infiltrate around an intestinal crypt. Ulceration then develops,\u00a0initially involving only\u00a0the superficial mucosa but later growing into the deeper layers. Noncaseating granulomas develop with continuing inflammation, spreading toward the intestinal wall. Granuloma formation is seen in up to 33% of patients with Crohn disease,\u00a0but their absence does not exclude the diagnosis."}
{"id": "article-20133_25", "title": "Crohn Disease -- Histopathology", "content": "The classic mucosal cobblestone appearance with skip lesions develops along the length of the bowel\u00a0and intervening areas of normal mucosa. Resolution of acute episodes results in scarring in previously inflamed intestinal areas. [17] Repeated inflammation-and-scarring cycles\u00a0can lead to stricture formation and bowel obstruction. Inflammation can spread to\u00a0adjacent organs, which may manifest as enterovesicular, enteroenteral, enterocutaneous, and enterovaginal fistulae.", "contents": "Crohn Disease -- Histopathology. The classic mucosal cobblestone appearance with skip lesions develops along the length of the bowel\u00a0and intervening areas of normal mucosa. Resolution of acute episodes results in scarring in previously inflamed intestinal areas. [17] Repeated inflammation-and-scarring cycles\u00a0can lead to stricture formation and bowel obstruction. Inflammation can spread to\u00a0adjacent organs, which may manifest as enterovesicular, enteroenteral, enterocutaneous, and enterovaginal fistulae."}
{"id": "article-20133_26", "title": "Crohn Disease -- History and Physical -- History", "content": "Crohn disease manifests variably, depending on the area involved. Patients initially report recurrent episodes of mild abdominal pain, diarrhea, flatulence, and fever with intervening asymptomatic periods lasting weeks to months. Emotional or physical stress often precipitates the \"flare\" or \"flare-up\" symptoms. More serious, localizing signs start to appear after repeated flare-ups. A family history of IBD may or may not be reported.", "contents": "Crohn Disease -- History and Physical -- History. Crohn disease manifests variably, depending on the area involved. Patients initially report recurrent episodes of mild abdominal pain, diarrhea, flatulence, and fever with intervening asymptomatic periods lasting weeks to months. Emotional or physical stress often precipitates the \"flare\" or \"flare-up\" symptoms. More serious, localizing signs start to appear after repeated flare-ups. A family history of IBD may or may not be reported."}
{"id": "article-20133_27", "title": "Crohn Disease -- History and Physical -- Ileocolic involvement", "content": "Patients with ileocolitis typically report recurrent RLQ pain and diarrhea. The pain may be described as colicky and relieved by defecation. Crohn disease may present similarly to acute appendicitis,\u00a0which also typically has fever, diarrhea, and RLQ pain as symptoms. An inflammatory RLQ mass may also be palpated in patients with CD.", "contents": "Crohn Disease -- History and Physical -- Ileocolic involvement. Patients with ileocolitis typically report recurrent RLQ pain and diarrhea. The pain may be described as colicky and relieved by defecation. Crohn disease may present similarly to acute appendicitis,\u00a0which also typically has fever, diarrhea, and RLQ pain as symptoms. An inflammatory RLQ mass may also be palpated in patients with CD."}
{"id": "article-20133_28", "title": "Crohn Disease -- History and Physical -- Ileocolic involvement", "content": "A low-grade fever is more typical of Crohn disease. A different pathology, such as an intraabdominal abscess, must be suspected in the presence of a high-grade fever. Weight loss often develops due to diarrhea and fear of eating.", "contents": "Crohn Disease -- History and Physical -- Ileocolic involvement. A low-grade fever is more typical of Crohn disease. A different pathology, such as an intraabdominal abscess, must be suspected in the presence of a high-grade fever. Weight loss often develops due to diarrhea and fear of eating."}
{"id": "article-20133_29", "title": "Crohn Disease -- History and Physical -- Ileocolic involvement", "content": "Years of recurrent inflammation typically lead to fibrostenosis and stricture formation in the ileocecal area. Diarrhea is later replaced by chronic bowel obstruction. Ileocecal wall thinning eventually occurs, leading to microperforation and fistula formation into\u00a0nearby organs. Dysuria, pneumaturia, and recurrent urinary tract infections are often due to enterovesical fistulae. Enterocutaneous fistulae may manifest as surgical scar drainage, as surgical scars are relatively weaker areas than intact skin. Dyspareunia and feculent vaginal discharge may signify an enterovaginal fistula.", "contents": "Crohn Disease -- History and Physical -- Ileocolic involvement. Years of recurrent inflammation typically lead to fibrostenosis and stricture formation in the ileocecal area. Diarrhea is later replaced by chronic bowel obstruction. Ileocecal wall thinning eventually occurs, leading to microperforation and fistula formation into\u00a0nearby organs. Dysuria, pneumaturia, and recurrent urinary tract infections are often due to enterovesical fistulae. Enterocutaneous fistulae may manifest as surgical scar drainage, as surgical scars are relatively weaker areas than intact skin. Dyspareunia and feculent vaginal discharge may signify an enterovaginal fistula."}
{"id": "article-20133_30", "title": "Crohn Disease -- History and Physical -- Jejunoileal disease", "content": "Involvement of these small bowel regions often causes malabsorption and steatorrhea. Nutritional deficiencies consequently arise, compounded by poor eating. Nutrients that may be lost to chronic diarrhea include iron, albumin, calcium, magnesium, fat-soluble vitamins (A, D, E, and K), niacin, folic acid, vitamin B 12 , and trace minerals like zinc, selenium, and copper. Patients may present with symptoms attributable to insufficient levels of specific nutrients.\u00a0Individuals with jejunoileal pathology may also develop fistulae and electrolyte imbalance.", "contents": "Crohn Disease -- History and Physical -- Jejunoileal disease. Involvement of these small bowel regions often causes malabsorption and steatorrhea. Nutritional deficiencies consequently arise, compounded by poor eating. Nutrients that may be lost to chronic diarrhea include iron, albumin, calcium, magnesium, fat-soluble vitamins (A, D, E, and K), niacin, folic acid, vitamin B 12 , and trace minerals like zinc, selenium, and copper. Patients may present with symptoms attributable to insufficient levels of specific nutrients.\u00a0Individuals with jejunoileal pathology may also develop fistulae and electrolyte imbalance."}
{"id": "article-20133_31", "title": "Crohn Disease -- History and Physical -- Colitis with perianal involvement", "content": "More characteristic of this condition are\u00a0manifestations like hematochezia, pain on defecation, reduced rectal wall elasticity, incontinence, anorectal pain and fistulae, perirectal abscesses, anal strictures, and hemorrhoidal tags. Bowel obstruction may result from colonic stricturing, which may warrant surgery. Fistulization into the stomach may cause feculent emesis. Fistulization into the small bowel may manifest as bacterial overgrowth and malabsorption. Rectovaginal fistula can also develop in women with this condition.", "contents": "Crohn Disease -- History and Physical -- Colitis with perianal involvement. More characteristic of this condition are\u00a0manifestations like hematochezia, pain on defecation, reduced rectal wall elasticity, incontinence, anorectal pain and fistulae, perirectal abscesses, anal strictures, and hemorrhoidal tags. Bowel obstruction may result from colonic stricturing, which may warrant surgery. Fistulization into the stomach may cause feculent emesis. Fistulization into the small bowel may manifest as bacterial overgrowth and malabsorption. Rectovaginal fistula can also develop in women with this condition."}
{"id": "article-20133_32", "title": "Crohn Disease -- History and Physical -- Gastroduodenal pathology", "content": "Upper gastrointestinal tract symptoms are more common in patients with this condition than in the other forms of Crohn disease. Such symptoms include emesis, nausea, and epigastric pain. Gastric ulcer diagnostic workups are likely to reveal the absence of H pylori . Upper gastrointestinal obstruction is common. Children may develop esophageal involvement.", "contents": "Crohn Disease -- History and Physical -- Gastroduodenal pathology. Upper gastrointestinal tract symptoms are more common in patients with this condition than in the other forms of Crohn disease. Such symptoms include emesis, nausea, and epigastric pain. Gastric ulcer diagnostic workups are likely to reveal the absence of H pylori . Upper gastrointestinal obstruction is common. Children may develop esophageal involvement."}
{"id": "article-20133_33", "title": "Crohn Disease -- History and Physical -- Extraintestinal manifestations", "content": "Crohn disease is associated with extraintestinal manifestations involving various organs. These conditions include the following: [18] Eyes: episcleritis, scleritis, uveitis Mouth: stomatitis, aphthous ulcers Liver: gallstones, cholangitis, primary sclerosing cholangitis Kidneys: nephrolithiasis, hydronephrosis, urinary tract infections Joints: axial (ankylosing spondylitis) or peripheral (knees, ankles, wrists, elbows) arthritis Skin: erythema nodosum and pyoderma gangrenosum", "contents": "Crohn Disease -- History and Physical -- Extraintestinal manifestations. Crohn disease is associated with extraintestinal manifestations involving various organs. These conditions include the following: [18] Eyes: episcleritis, scleritis, uveitis Mouth: stomatitis, aphthous ulcers Liver: gallstones, cholangitis, primary sclerosing cholangitis Kidneys: nephrolithiasis, hydronephrosis, urinary tract infections Joints: axial (ankylosing spondylitis) or peripheral (knees, ankles, wrists, elbows) arthritis Skin: erythema nodosum and pyoderma gangrenosum"}
{"id": "article-20133_34", "title": "Crohn Disease -- History and Physical -- Extraintestinal manifestations", "content": "Crohn disease also induces a hypercoagulable state, increasing the risk of thromboembolic disease. [19] Decreased mobility in hospitalized patients may result in deep vein thrombosis, stroke, or pulmonary embolism.", "contents": "Crohn Disease -- History and Physical -- Extraintestinal manifestations. Crohn disease also induces a hypercoagulable state, increasing the risk of thromboembolic disease. [19] Decreased mobility in hospitalized patients may result in deep vein thrombosis, stroke, or pulmonary embolism."}
{"id": "article-20133_35", "title": "Crohn Disease -- History and Physical -- Physical Examination", "content": "A thorough physical examination with a detailed abdominal assessment is crucial for patients with abdominal complaints. General assessment in individuals with Crohn disease may reveal signs of malnutrition like pallor and low weight. Vital signs assessment of these patients may reveal fever, tachycardia, and hypotension.", "contents": "Crohn Disease -- History and Physical -- Physical Examination. A thorough physical examination with a detailed abdominal assessment is crucial for patients with abdominal complaints. General assessment in individuals with Crohn disease may reveal signs of malnutrition like pallor and low weight. Vital signs assessment of these patients may reveal fever, tachycardia, and hypotension."}
{"id": "article-20133_36", "title": "Crohn Disease -- History and Physical -- Physical Examination", "content": "Abdominal inspection may reveal enterocutaneous fistulae in patients with advanced disease. Hyperactive bowel sounds may indicate inflammation or obstruction, while absent bowel sounds may suggest ileus or severe inflammation. Palpation may reveal tenderness localizing to the intestinal area involved. Guarding is a sign of peritonitis in individuals with intraabdominal perforation or abscess. Individuals with advanced perianal disease may have perianal fistulae or hemorrhoids, necessitating a digital rectal examination.", "contents": "Crohn Disease -- History and Physical -- Physical Examination. Abdominal inspection may reveal enterocutaneous fistulae in patients with advanced disease. Hyperactive bowel sounds may indicate inflammation or obstruction, while absent bowel sounds may suggest ileus or severe inflammation. Palpation may reveal tenderness localizing to the intestinal area involved. Guarding is a sign of peritonitis in individuals with intraabdominal perforation or abscess. Individuals with advanced perianal disease may have perianal fistulae or hemorrhoids, necessitating a digital rectal examination."}
{"id": "article-20133_37", "title": "Crohn Disease -- History and Physical -- Physical Examination", "content": "The skin, eyes, oral cavity, and joints must be examined for extraintestinal manifestations of Crohn disease. Liver involvement may manifest with right upper quadrant tenderness and jaundice. Renal damage must be suspected in the presence of flank tenderness and genitourinary abnormalities like genital fistulae and perineal skin tags. Female patients with gynecological complaints must undergo a pelvic examination. Neurologic deficits may be elicited in patients with vitamin deficiencies. Diminished sensation, muscle atrophy, and gait abnormalities may be observed.", "contents": "Crohn Disease -- History and Physical -- Physical Examination. The skin, eyes, oral cavity, and joints must be examined for extraintestinal manifestations of Crohn disease. Liver involvement may manifest with right upper quadrant tenderness and jaundice. Renal damage must be suspected in the presence of flank tenderness and genitourinary abnormalities like genital fistulae and perineal skin tags. Female patients with gynecological complaints must undergo a pelvic examination. Neurologic deficits may be elicited in patients with vitamin deficiencies. Diminished sensation, muscle atrophy, and gait abnormalities may be observed."}
{"id": "article-20133_38", "title": "Crohn Disease -- History and Physical -- Physical Examination", "content": "Overall, a thorough physical examination of patients with Crohn disease can help identify active inflammation, assess disease severity, detect complications, and guide further diagnostic evaluation and management.", "contents": "Crohn Disease -- History and Physical -- Physical Examination. Overall, a thorough physical examination of patients with Crohn disease can help identify active inflammation, assess disease severity, detect complications, and guide further diagnostic evaluation and management."}
{"id": "article-20133_39", "title": "Crohn Disease -- Evaluation -- Laboratory Tests", "content": "Stool tests to rule out infections include culture and sensitivities, ovum and parasites, and C. difficile toxins. Stool calprotectin can detect active Crohn disease and is used for monitoring disease activity. [20] [21] [22] [23]", "contents": "Crohn Disease -- Evaluation -- Laboratory Tests. Stool tests to rule out infections include culture and sensitivities, ovum and parasites, and C. difficile toxins. Stool calprotectin can detect active Crohn disease and is used for monitoring disease activity. [20] [21] [22] [23]"}
{"id": "article-20133_40", "title": "Crohn Disease -- Evaluation -- Laboratory Tests", "content": "Blood tests, including a complete blood count and a metabolic panel, may reveal anemia (due to vitamin B12 or iron deficiency) and liver disease. Electrolytes may be deranged due to diarrhea. Increased creatinine, blood urea nitrogen, and liver enzymes may indicate renal and liver involvement, respectively. Urinalysis may reveal bacteriuria and leukocyturia. Specific nutrient deficiencies, eg, iron and calcium, may be documented by taking serum levels if the test results\u00a0can be used\u00a0to correct the problem.", "contents": "Crohn Disease -- Evaluation -- Laboratory Tests. Blood tests, including a complete blood count and a metabolic panel, may reveal anemia (due to vitamin B12 or iron deficiency) and liver disease. Electrolytes may be deranged due to diarrhea. Increased creatinine, blood urea nitrogen, and liver enzymes may indicate renal and liver involvement, respectively. Urinalysis may reveal bacteriuria and leukocyturia. Specific nutrient deficiencies, eg, iron and calcium, may be documented by taking serum levels if the test results\u00a0can be used\u00a0to correct the problem."}
{"id": "article-20133_41", "title": "Crohn Disease -- Evaluation -- Laboratory Tests", "content": "Special serologic tests, such as antineutrophil cytoplasmic and anti- Saccharomyces cerevisiae antibodies, are not routinely indicated to distinguish Crohn disease from ulcerative colitis. C-reactive protein (CRP) or erythrocyte sedimentary rate elevation may reflect inflammation severity. [24] [25]", "contents": "Crohn Disease -- Evaluation -- Laboratory Tests. Special serologic tests, such as antineutrophil cytoplasmic and anti- Saccharomyces cerevisiae antibodies, are not routinely indicated to distinguish Crohn disease from ulcerative colitis. C-reactive protein (CRP) or erythrocyte sedimentary rate elevation may reflect inflammation severity. [24] [25]"}
{"id": "article-20133_42", "title": "Crohn Disease -- Evaluation -- Imaging", "content": "Plain x-rays should be ordered if bowel obstruction is suspected. Small bowel follow-through is often used to assess terminal ileal involvement. This modality can also detect fistulas. The classic string sign due to stricture formation or spasm is often seen.", "contents": "Crohn Disease -- Evaluation -- Imaging. Plain x-rays should be ordered if bowel obstruction is suspected. Small bowel follow-through is often used to assess terminal ileal involvement. This modality can also detect fistulas. The classic string sign due to stricture formation or spasm is often seen."}
{"id": "article-20133_43", "title": "Crohn Disease -- Evaluation -- Imaging", "content": "Gastroenterologists may perform a\u00a0quick abdominal ultrasound during flare-ups\u00a0or monitoring of treatment response (see Image . Periumbilical Fistula Ultrasonography). Ultrasound does not pose a radiation risk and is widely available, though the image may not have good resolution. Features that may be appreciated using this modality include fistulae, free intraperitoneal fluid, abscess formation, and increased superior mesenteric artery flow. The superior mesenteric artery often has increased flow volume during active disease that may be\u00a0documented by Doppler ultrasound.", "contents": "Crohn Disease -- Evaluation -- Imaging. Gastroenterologists may perform a\u00a0quick abdominal ultrasound during flare-ups\u00a0or monitoring of treatment response (see Image . Periumbilical Fistula Ultrasonography). Ultrasound does not pose a radiation risk and is widely available, though the image may not have good resolution. Features that may be appreciated using this modality include fistulae, free intraperitoneal fluid, abscess formation, and increased superior mesenteric artery flow. The superior mesenteric artery often has increased flow volume during active disease that may be\u00a0documented by Doppler ultrasound."}
{"id": "article-20133_44", "title": "Crohn Disease -- Evaluation -- Imaging", "content": "Abdominal and pelvic computed tomography (CT), magnetic resonance imaging (MRI), or enterography (MRE) can detect abscesses, strictures, and fistulization (see Image .\u00a0Crohn\u00a0Disease on Computed Tomography). Both give clearer images of the diseased intestine. However, MRI can provide more detail when investigating fistulizing disease. Additionally, MRI is preferable over CT in pediatric populations, as it\u00a0emanates little\u00a0ionizing radiation.", "contents": "Crohn Disease -- Evaluation -- Imaging. Abdominal and pelvic computed tomography (CT), magnetic resonance imaging (MRI), or enterography (MRE) can detect abscesses, strictures, and fistulization (see Image .\u00a0Crohn\u00a0Disease on Computed Tomography). Both give clearer images of the diseased intestine. However, MRI can provide more detail when investigating fistulizing disease. Additionally, MRI is preferable over CT in pediatric populations, as it\u00a0emanates little\u00a0ionizing radiation."}
{"id": "article-20133_45", "title": "Crohn Disease -- Evaluation -- Imaging", "content": "The bowel mucosa may be visualized by upper endoscopy and colonoscopy. Additionally, these modalities permit the assessment of the extent of bowel inflammation and tissue sample collection for disease confirmation. Endoscopic evaluation is also useful for assessing treatment response.", "contents": "Crohn Disease -- Evaluation -- Imaging. The bowel mucosa may be visualized by upper endoscopy and colonoscopy. Additionally, these modalities permit the assessment of the extent of bowel inflammation and tissue sample collection for disease confirmation. Endoscopic evaluation is also useful for assessing treatment response."}
{"id": "article-20133_46", "title": "Crohn Disease -- Evaluation -- Imaging", "content": "Video capsule endoscopy (VCE) can visualize the small bowel in patients with Crohn disease when regular endoscopy or colonoscopy cannot reach these areas. However, caution is advised in using VCE in the setting of known stricturing disease due to the potential for capsule retention within the strictured segment. Capsule endoscopy can only detect mucosal changes. In contrast, MRI can detect transmural inflammation and other complications.", "contents": "Crohn Disease -- Evaluation -- Imaging. Video capsule endoscopy (VCE) can visualize the small bowel in patients with Crohn disease when regular endoscopy or colonoscopy cannot reach these areas. However, caution is advised in using VCE in the setting of known stricturing disease due to the potential for capsule retention within the strictured segment. Capsule endoscopy can only detect mucosal changes. In contrast, MRI can detect transmural inflammation and other complications."}
{"id": "article-20133_47", "title": "Crohn Disease -- Evaluation -- Miscellaneous Tests", "content": "Crohn disease treatments suppress the immune system. The patient's vaccination history should thus be known before initiating the regimen. Vaccines to\u00a0inquire\u00a0about include tetanus, diphtheria, pertussis, human papillomavirus, influenza, pneumococcal, hepatitis A, hepatitis B, measles, mumps, rubella, varicella-zoster virus, and severe acute respiratory syndrome coronavirus 2.", "contents": "Crohn Disease -- Evaluation -- Miscellaneous Tests. Crohn disease treatments suppress the immune system. The patient's vaccination history should thus be known before initiating the regimen. Vaccines to\u00a0inquire\u00a0about include tetanus, diphtheria, pertussis, human papillomavirus, influenza, pneumococcal, hepatitis A, hepatitis B, measles, mumps, rubella, varicella-zoster virus, and severe acute respiratory syndrome coronavirus 2."}
{"id": "article-20133_48", "title": "Crohn Disease -- Evaluation -- Miscellaneous Tests", "content": "Obtain a baseline tuberculosis screen, particularly in patients initiating anti-TNF biologics. Screening for latent tuberculosis may include a combination of history, tuberculin skin test, interferon-\u03b3 release assay, and chest radiography. [26]", "contents": "Crohn Disease -- Evaluation -- Miscellaneous Tests. Obtain a baseline tuberculosis screen, particularly in patients initiating anti-TNF biologics. Screening for latent tuberculosis may include a combination of history, tuberculin skin test, interferon-\u03b3 release assay, and chest radiography. [26]"}
{"id": "article-20133_49", "title": "Crohn Disease -- Evaluation -- Miscellaneous Tests", "content": "Baseline thiopurine methyltransferase (TPMT) levels should be checked before deciding on treatment options. Low\u00a0TPMT levels may increase the risk of side effects, while very high levels may decrease the effectiveness of prescribed treatment.", "contents": "Crohn Disease -- Evaluation -- Miscellaneous Tests. Baseline thiopurine methyltransferase (TPMT) levels should be checked before deciding on treatment options. Low\u00a0TPMT levels may increase the risk of side effects, while very high levels may decrease the effectiveness of prescribed treatment."}
{"id": "article-20133_50", "title": "Crohn Disease -- Treatment / Management -- Medical Management", "content": "Medical treatment of Crohn disease is typically divided into the induction and maintenance phases. During induction, inflammation control is ideally achieved within 3 months. The maintenance phase aims to prolong the asymptomatic phase. The choice of medical therapy is based on the patient's risk profile and disease severity.", "contents": "Crohn Disease -- Treatment / Management -- Medical Management. Medical treatment of Crohn disease is typically divided into the induction and maintenance phases. During induction, inflammation control is ideally achieved within 3 months. The maintenance phase aims to prolong the asymptomatic phase. The choice of medical therapy is based on the patient's risk profile and disease severity."}
{"id": "article-20133_51", "title": "Crohn Disease -- Treatment / Management -- Medical Management", "content": "Mild-to-moderate disease can be treated by oral mesalamine, immunomodulators like thiopurines (6-mercaptopurine, azathioprine), methotrexate, and steroids.", "contents": "Crohn Disease -- Treatment / Management -- Medical Management. Mild-to-moderate disease can be treated by oral mesalamine, immunomodulators like thiopurines (6-mercaptopurine, azathioprine), methotrexate, and steroids."}
{"id": "article-20133_52", "title": "Crohn Disease -- Treatment / Management -- Medical Management", "content": "Mesalamines (5-ASAs) and sulfasalazine (5-ASA with a sulfapyridine moiety) exert an anti-inflammatory effect. The use of 5-ASAs is not as well-established in Crohn disease as in ulcerative colitis. While these medications may be tried in mild colonic Crohn disease, use in small bowel disease is not effective. [27] Corticosteroids are primarily used to induce Crohn disease flare remission and stabilize the condition until immunomodulator or biologic therapy takes effect, particularly in moderate-to-severe Crohn disease. However, prolonged corticosteroid use, eg, for maintenance, is avoided due to chronic side effects like osteoporosis, osteonecrosis, and adrenal insufficiency. Immunomodulators are steroid-sparing drugs effective in the maintenance therapy of moderate Crohn disease. These medications have a relatively slow action onset\u2014between 8\u00a0to 12 weeks\u2014and are thus not used for active Crohn disease induction remission. However, immunomodulators may be initially combined with steroids. [28] [29] [30] [31] Dosages for Crohn disease are azathioprine 1.5 to 2.5 mg/kg/day, 6-mercaptopurine 0.75 to 1.5 mg/kg day, and methotrexate (MTX) 15 to 25 mg once weekly. TPMT is the main enzyme that inactivates toxic thiopurine metabolites. A low TPMT level can increase the risk of side effects, while a high level can reduce treatment potency. [32] MTX is teratogenic and may affect spermatogenesis. Thus, women of childbearing age and men should be counseled to use contraception within 3 months of MTX use.", "contents": "Crohn Disease -- Treatment / Management -- Medical Management. Mesalamines (5-ASAs) and sulfasalazine (5-ASA with a sulfapyridine moiety) exert an anti-inflammatory effect. The use of 5-ASAs is not as well-established in Crohn disease as in ulcerative colitis. While these medications may be tried in mild colonic Crohn disease, use in small bowel disease is not effective. [27] Corticosteroids are primarily used to induce Crohn disease flare remission and stabilize the condition until immunomodulator or biologic therapy takes effect, particularly in moderate-to-severe Crohn disease. However, prolonged corticosteroid use, eg, for maintenance, is avoided due to chronic side effects like osteoporosis, osteonecrosis, and adrenal insufficiency. Immunomodulators are steroid-sparing drugs effective in the maintenance therapy of moderate Crohn disease. These medications have a relatively slow action onset\u2014between 8\u00a0to 12 weeks\u2014and are thus not used for active Crohn disease induction remission. However, immunomodulators may be initially combined with steroids. [28] [29] [30] [31] Dosages for Crohn disease are azathioprine 1.5 to 2.5 mg/kg/day, 6-mercaptopurine 0.75 to 1.5 mg/kg day, and methotrexate (MTX) 15 to 25 mg once weekly. TPMT is the main enzyme that inactivates toxic thiopurine metabolites. A low TPMT level can increase the risk of side effects, while a high level can reduce treatment potency. [32] MTX is teratogenic and may affect spermatogenesis. Thus, women of childbearing age and men should be counseled to use contraception within 3 months of MTX use."}
{"id": "article-20133_53", "title": "Crohn Disease -- Treatment / Management -- Medical Management", "content": "Moderate-to-severe disease (including fistulizing disease) is best treated with combined immunomodulators and biologics or biologics alone.", "contents": "Crohn Disease -- Treatment / Management -- Medical Management. Moderate-to-severe disease (including fistulizing disease) is best treated with combined immunomodulators and biologics or biologics alone."}
{"id": "article-20133_54", "title": "Crohn Disease -- Treatment / Management -- Medical Management", "content": "Corticosteroids are primarily used to induce remission in moderate-to-severe Crohn disease and should be used sparingly to avoid side effects. Immunomodulators serve as adjuncts that reduce immunogenicity against biologics. Notably, combination therapy with an immunomodulator and anti-TNF is more effective than monotherapy with either medication. [33] Anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) block the downstream effects of the TNF inflammatory cascade. These agents are efficacious in steroid-resistant or immunomodulator-refractory Crohn disease. The effect onset is relatively rapid, with clinical benefit seen within 2 weeks of initiation. Anti-TNF drugs are effective in treating fistulizing disease and reducing the risk of postsurgical endoscopic recurrence. [34] However, caution is advised when using these agents in patients with a history of demyelinating disease, congestive heart failure, and malignancies like lymphoma. [35] Recent data demonstrate no associated increase in adverse maternal-fetal outcomes in pregnant patients exposed to anti-TNF therapy. [36] Leukocyte trafficking agents selectively inhibit an adhesion protein (integrin \u03b14\u03b27) on a memory T cell subset, preventing the T cells' binding to gut mucosal cells. This action mechanism produces gut-specific anti-inflammatory effects. Vedolizumab is the agent in this class used in Crohn disease. This drug was found to be more effective than placebo in inducing and maintaining remission in Crohn disease, with or without immunomodulators. [37] However, the time to clinical effect may be slower (around 10 weeks) than anti-TNF agents, particularly in patients previously on anti-TNF therapy. [38] Gut-specific actions limit vedolizumab's toxicity. Thus, this drug's side effect profile is relatively favorable. IL-12/23 agents (ustekinumab, risankizumab) are efficacious in patients who failed prior corticosteroid, immunomodulator, or anti-TNF treatment. [39] [40] [41] Ustekinumab is a nonselective IL-12/23 inhibitor, while risankizumab is a selective IL-23 inhibitor. The side effect profile of these agents is relatively favorable according to safety surveillance data in psoriasis patients. [42] JAK inhibitors target Janus kinases that contribute to abnormal immune responses. Upadacitinib is the first FDA-approved oral selective JAK inhibitor therapy for Crohn disease. This medication is efficacious in patients who previously failed conventional and biologic Crohn disease therapies. [43] The onset of clinical effects is relatively rapid at 2 weeks. However, this drug increases Herpes Zoster risk. Thus, the shingles vaccine is recommended before treatment initiation. Use of upadacitinib during pregnancy is not advised due to findings of teratogenicity in animal studies. [44]", "contents": "Crohn Disease -- Treatment / Management -- Medical Management. Corticosteroids are primarily used to induce remission in moderate-to-severe Crohn disease and should be used sparingly to avoid side effects. Immunomodulators serve as adjuncts that reduce immunogenicity against biologics. Notably, combination therapy with an immunomodulator and anti-TNF is more effective than monotherapy with either medication. [33] Anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) block the downstream effects of the TNF inflammatory cascade. These agents are efficacious in steroid-resistant or immunomodulator-refractory Crohn disease. The effect onset is relatively rapid, with clinical benefit seen within 2 weeks of initiation. Anti-TNF drugs are effective in treating fistulizing disease and reducing the risk of postsurgical endoscopic recurrence. [34] However, caution is advised when using these agents in patients with a history of demyelinating disease, congestive heart failure, and malignancies like lymphoma. [35] Recent data demonstrate no associated increase in adverse maternal-fetal outcomes in pregnant patients exposed to anti-TNF therapy. [36] Leukocyte trafficking agents selectively inhibit an adhesion protein (integrin \u03b14\u03b27) on a memory T cell subset, preventing the T cells' binding to gut mucosal cells. This action mechanism produces gut-specific anti-inflammatory effects. Vedolizumab is the agent in this class used in Crohn disease. This drug was found to be more effective than placebo in inducing and maintaining remission in Crohn disease, with or without immunomodulators. [37] However, the time to clinical effect may be slower (around 10 weeks) than anti-TNF agents, particularly in patients previously on anti-TNF therapy. [38] Gut-specific actions limit vedolizumab's toxicity. Thus, this drug's side effect profile is relatively favorable. IL-12/23 agents (ustekinumab, risankizumab) are efficacious in patients who failed prior corticosteroid, immunomodulator, or anti-TNF treatment. [39] [40] [41] Ustekinumab is a nonselective IL-12/23 inhibitor, while risankizumab is a selective IL-23 inhibitor. The side effect profile of these agents is relatively favorable according to safety surveillance data in psoriasis patients. [42] JAK inhibitors target Janus kinases that contribute to abnormal immune responses. Upadacitinib is the first FDA-approved oral selective JAK inhibitor therapy for Crohn disease. This medication is efficacious in patients who previously failed conventional and biologic Crohn disease therapies. [43] The onset of clinical effects is relatively rapid at 2 weeks. However, this drug increases Herpes Zoster risk. Thus, the shingles vaccine is recommended before treatment initiation. Use of upadacitinib during pregnancy is not advised due to findings of teratogenicity in animal studies. [44]"}
{"id": "article-20133_55", "title": "Crohn Disease -- Treatment / Management -- Medical Management", "content": "In 2021, the American Gastroenterology Association (AGA) published perianal and fistulizing Crohn disease management guidelines strongly recommending infliximab over no treatment for inducing and maintaining disease remission. This biologic is the only medication with dedicated randomized controlled trial (RCT) data demonstrating efficacy. [45] The AGA also strongly recommended combining biologic agents with an antibiotic instead of using biologic monotherapy for inducing fistula healing. This recommendation was based on 2 RCTs showing that\u00a0anti-TNF agents combined with ciprofloxacin were more efficacious in\u00a0inducing fistula remission than anti-TNF\u00a0monotherapy.", "contents": "Crohn Disease -- Treatment / Management -- Medical Management. In 2021, the American Gastroenterology Association (AGA) published perianal and fistulizing Crohn disease management guidelines strongly recommending infliximab over no treatment for inducing and maintaining disease remission. This biologic is the only medication with dedicated randomized controlled trial (RCT) data demonstrating efficacy. [45] The AGA also strongly recommended combining biologic agents with an antibiotic instead of using biologic monotherapy for inducing fistula healing. This recommendation was based on 2 RCTs showing that\u00a0anti-TNF agents combined with ciprofloxacin were more efficacious in\u00a0inducing fistula remission than anti-TNF\u00a0monotherapy."}
{"id": "article-20133_56", "title": "Crohn Disease -- Treatment / Management -- Surgical Management", "content": "Surgery is warranted when Crohn disease complications arise, such as bowel obstruction from fibrostenotic strictures, fistulization despite appropriate medical therapy, recurrent abscesses, perforated bowel, dysplasia, cancer, or medically refractory disease. Surgical resection and stricturoplasty are options for managing fibrostenotic disease, the most common surgical indication (see Image . Subtotal\u00a0Colectomy in\u00a0Severe Crohn\u00a0Colitis). Short segment strictures may be considered for endoscopic dilation.", "contents": "Crohn Disease -- Treatment / Management -- Surgical Management. Surgery is warranted when Crohn disease complications arise, such as bowel obstruction from fibrostenotic strictures, fistulization despite appropriate medical therapy, recurrent abscesses, perforated bowel, dysplasia, cancer, or medically refractory disease. Surgical resection and stricturoplasty are options for managing fibrostenotic disease, the most common surgical indication (see Image . Subtotal\u00a0Colectomy in\u00a0Severe Crohn\u00a0Colitis). Short segment strictures may be considered for endoscopic dilation."}
{"id": "article-20133_57", "title": "Crohn Disease -- Treatment / Management -- Surgical Management", "content": "Fistulotomy may be performed for simple fistulas, defined as superficial or low transsphincteric fistulas without associated proctitis. Complex fistulas may warrant chronic seton placement. Mesenchymal stem cell injection into the fistula pathway to reduce inflammation shows promise and is undergoing investigation. [46]", "contents": "Crohn Disease -- Treatment / Management -- Surgical Management. Fistulotomy may be performed for simple fistulas, defined as superficial or low transsphincteric fistulas without associated proctitis. Complex fistulas may warrant chronic seton placement. Mesenchymal stem cell injection into the fistula pathway to reduce inflammation shows promise and is undergoing investigation. [46]"}
{"id": "article-20133_58", "title": "Crohn Disease -- Treatment / Management -- Surgical Management", "content": "The American Society of Colon and Rectal Surgeons recommends total colectomy with ileorectal anastomosis or total proctocolectomy for patients with Crohn colitis with dysplasia not amenable to endoscopic resection. Other recommended indications are multifocal dysplasia and colorectal cancer. The recommendation is based on the increased metachronous colorectal cancer risk (14-40%) and high multifocal dysplasia rates in patients with Crohn's colitis who underwent colectomy for low- or high-grade dysplasia. [47] [48] [49]", "contents": "Crohn Disease -- Treatment / Management -- Surgical Management. The American Society of Colon and Rectal Surgeons recommends total colectomy with ileorectal anastomosis or total proctocolectomy for patients with Crohn colitis with dysplasia not amenable to endoscopic resection. Other recommended indications are multifocal dysplasia and colorectal cancer. The recommendation is based on the increased metachronous colorectal cancer risk (14-40%) and high multifocal dysplasia rates in patients with Crohn's colitis who underwent colectomy for low- or high-grade dysplasia. [47] [48] [49]"}
{"id": "article-20133_59", "title": "Crohn Disease -- Treatment / Management -- Surgical Management", "content": "A diverting ileostomy rather than primary anastomosis is usually considered when performing ileocolectomy in Crohn disease patients with multiple risk factors for an anastomotic leak. Such risk factors include smoking, steroid use, and weight loss. [47]", "contents": "Crohn Disease -- Treatment / Management -- Surgical Management. A diverting ileostomy rather than primary anastomosis is usually considered when performing ileocolectomy in Crohn disease patients with multiple risk factors for an anastomotic leak. Such risk factors include smoking, steroid use, and weight loss. [47]"}
{"id": "article-20133_60", "title": "Crohn Disease -- Treatment / Management -- Surgical Management", "content": "Residual postsurgical disease or high postsurgical recurrence risk warrants postoperative biologic therapy, eg, with an anti-TNF agent, 2 to 4 weeks after surgery if postoperative infections have been ruled out. [47]", "contents": "Crohn Disease -- Treatment / Management -- Surgical Management. Residual postsurgical disease or high postsurgical recurrence risk warrants postoperative biologic therapy, eg, with an anti-TNF agent, 2 to 4 weeks after surgery if postoperative infections have been ruled out. [47]"}
{"id": "article-20133_61", "title": "Crohn Disease -- Treatment / Management -- Treatment Monitoring", "content": "The AGA recommended in 2023 that monitoring Crohn disease treatment response should be based on the presence of clinical symptoms and biomarker levels. [50] Biomarkers may be\u00a0taken every 6 to 12 months in patients in remission and more frequently in those requiring therapy titration.", "contents": "Crohn Disease -- Treatment / Management -- Treatment Monitoring. The AGA recommended in 2023 that monitoring Crohn disease treatment response should be based on the presence of clinical symptoms and biomarker levels. [50] Biomarkers may be\u00a0taken every 6 to 12 months in patients in remission and more frequently in those requiring therapy titration."}
{"id": "article-20133_62", "title": "Crohn Disease -- Treatment / Management -- Treatment Monitoring", "content": "Suggested biomarkers are fecal calprotectin and serum CRP. Targets should be less than 150 \u03bcg/g for calprotectin and less than 5 mg/L for CRP to rule out active inflammation and avoid routine endoscopic evaluation of disease activity. The AGA further recommended the following: Endoscopic or radiologic confirmation of disease remission within 3 years of symptomatic remission Biomarkers every 2 to 4 months to assess therapeutic response during active disease A follow-up endoscopy should be performed 6 to 12 months\u00a0after symptom resolution to document mucosal healing.", "contents": "Crohn Disease -- Treatment / Management -- Treatment Monitoring. Suggested biomarkers are fecal calprotectin and serum CRP. Targets should be less than 150 \u03bcg/g for calprotectin and less than 5 mg/L for CRP to rule out active inflammation and avoid routine endoscopic evaluation of disease activity. The AGA further recommended the following: Endoscopic or radiologic confirmation of disease remission within 3 years of symptomatic remission Biomarkers every 2 to 4 months to assess therapeutic response during active disease A follow-up endoscopy should be performed 6 to 12 months\u00a0after symptom resolution to document mucosal healing."}
{"id": "article-20133_63", "title": "Crohn Disease -- Treatment / Management -- Treatment Monitoring", "content": "A fecal calprotectin of less than 50 \u03bcg/g is sufficient to rule out disease recurrence in patients who have remained asymptomatic 12 months after surgical remission. Routine endoscopic assessment is not required in these patients. The same biomarker and target may be used in asymptomatic individuals with low postoperative recurrence risk or higher postoperative recurrence risk but already on prophylactic medication. High-risk patients not on prophylactic medication should undergo endoscopic evaluation for disease activity assessment.", "contents": "Crohn Disease -- Treatment / Management -- Treatment Monitoring. A fecal calprotectin of less than 50 \u03bcg/g is sufficient to rule out disease recurrence in patients who have remained asymptomatic 12 months after surgical remission. Routine endoscopic assessment is not required in these patients. The same biomarker and target may be used in asymptomatic individuals with low postoperative recurrence risk or higher postoperative recurrence risk but already on prophylactic medication. High-risk patients not on prophylactic medication should undergo endoscopic evaluation for disease activity assessment."}
{"id": "article-20133_64", "title": "Crohn Disease -- Treatment / Management -- Dietary Management", "content": "Diet remains an adjunctive therapy. Dietitian input and nutritional supplementation are highly recommended during Crohn disease treatment, as symptomatic patients are at risk for malnutrition and micronutrient deficiencies. For example, individuals with a history of terminal ileum inflammation or resection are at higher risk for vitamin B12 deficiency. [51] [52] [53] [54]", "contents": "Crohn Disease -- Treatment / Management -- Dietary Management. Diet remains an adjunctive therapy. Dietitian input and nutritional supplementation are highly recommended during Crohn disease treatment, as symptomatic patients are at risk for malnutrition and micronutrient deficiencies. For example, individuals with a history of terminal ileum inflammation or resection are at higher risk for vitamin B12 deficiency. [51] [52] [53] [54]"}
{"id": "article-20133_65", "title": "Crohn Disease -- Treatment / Management -- Dietary Management", "content": "Data predominantly from the pediatric population show that certain dietary therapies, such as elemental and semielemental diets, effectively reduce mucosal inflammation. [55] However, these diets have been largely unsuccessful in adults due to poor adherence. Benefits are also not durable due to inflammation recurrence after resuming a nonrestrictive diet.", "contents": "Crohn Disease -- Treatment / Management -- Dietary Management. Data predominantly from the pediatric population show that certain dietary therapies, such as elemental and semielemental diets, effectively reduce mucosal inflammation. [55] However, these diets have been largely unsuccessful in adults due to poor adherence. Benefits are also not durable due to inflammation recurrence after resuming a nonrestrictive diet."}
{"id": "article-20133_66", "title": "Crohn Disease -- Differential Diagnosis", "content": "The differential diagnoses to consider when assessing patients with possible Crohn disease are listed below.\u00a0Documentation of travel and exposure history\u00a0and judicious use of\u00a0laboratory, imaging, and histologic\u00a0tests help differentiate the above diagnoses. Infectious\u00a0enteritis and terminal ileitis Coccidioides Histoplasma Salmonella Tuberculosis Yersinia Infectious colitis Amebiasis Campylobacter C.difficile Cytomegalovirus E.coli Salmonella Shigella Noninfectious Behcet disease Common variable immunodeficiency Diverticulitis Drug-induced colitis, eg, from nonsteroidal anti-inflammatory drugs and immunotherapy Ischemic colitis Sarcoidosis Segmental colitis associated with diverticulosis Small vessel vasculitis Solitary rectal ulcer syndrome", "contents": "Crohn Disease -- Differential Diagnosis. The differential diagnoses to consider when assessing patients with possible Crohn disease are listed below.\u00a0Documentation of travel and exposure history\u00a0and judicious use of\u00a0laboratory, imaging, and histologic\u00a0tests help differentiate the above diagnoses. Infectious\u00a0enteritis and terminal ileitis Coccidioides Histoplasma Salmonella Tuberculosis Yersinia Infectious colitis Amebiasis Campylobacter C.difficile Cytomegalovirus E.coli Salmonella Shigella Noninfectious Behcet disease Common variable immunodeficiency Diverticulitis Drug-induced colitis, eg, from nonsteroidal anti-inflammatory drugs and immunotherapy Ischemic colitis Sarcoidosis Segmental colitis associated with diverticulosis Small vessel vasculitis Solitary rectal ulcer syndrome"}
{"id": "article-20133_67", "title": "Crohn Disease -- Prognosis", "content": "High-risk patients with moderate-to-severe Crohn disease often have the following characteristics: Relatively younger age, ie, younger than 30 years History of active or recent tobacco consumption Elevated CRP or fecal calprotectin levels Deep ulcers on colonoscopy Involvement of long bowel segments Perianal disease Extraintestinal manifestations History of bowel resections [56] [57]", "contents": "Crohn Disease -- Prognosis. High-risk patients with moderate-to-severe Crohn disease often have the following characteristics: Relatively younger age, ie, younger than 30 years History of active or recent tobacco consumption Elevated CRP or fecal calprotectin levels Deep ulcers on colonoscopy Involvement of long bowel segments Perianal disease Extraintestinal manifestations History of bowel resections [56] [57]"}
{"id": "article-20133_68", "title": "Crohn Disease -- Prognosis", "content": "Without immunomodulator or biologic therapy, up to 50% of patients\u00a0may become steroid-dependent or treatment-resistant, with a cumulative incidence of abdominal surgery of 46.6% 10 years after diagnosis. [58] The postsurgical endoscopic recurrence risk at or above the surgical anastomosis\u00a0is around 90%. Risk factors for early recurrence include cigarette smoking, short duration between Crohn disease diagnosis to the first surgery, need for multiple resections, and penetrating disease. [59] Surveillance endoscopy is recommended in\u00a06 to 12 months once a patient has had surgery.\u00a0Ileocolonoscopy should be repeated in 1 to 3 years without endoscopic recurrence.", "contents": "Crohn Disease -- Prognosis. Without immunomodulator or biologic therapy, up to 50% of patients\u00a0may become steroid-dependent or treatment-resistant, with a cumulative incidence of abdominal surgery of 46.6% 10 years after diagnosis. [58] The postsurgical endoscopic recurrence risk at or above the surgical anastomosis\u00a0is around 90%. Risk factors for early recurrence include cigarette smoking, short duration between Crohn disease diagnosis to the first surgery, need for multiple resections, and penetrating disease. [59] Surveillance endoscopy is recommended in\u00a06 to 12 months once a patient has had surgery.\u00a0Ileocolonoscopy should be repeated in 1 to 3 years without endoscopic recurrence."}
{"id": "article-20133_69", "title": "Crohn Disease -- Prognosis", "content": "Prior meta-analyses show a slight mortality risk in patients with Crohn disease, with a standardized pooled mortality ratio of 1.4\u00a0to 1.5 compared to the general population. This\u00a0outcome is attributable to gastrointestinal disease, gastrointestinal cancer, and pulmonary disease. [60] [61] Current corticosteroid use is further associated with\u00a0increased mortality. [62]", "contents": "Crohn Disease -- Prognosis. Prior meta-analyses show a slight mortality risk in patients with Crohn disease, with a standardized pooled mortality ratio of 1.4\u00a0to 1.5 compared to the general population. This\u00a0outcome is attributable to gastrointestinal disease, gastrointestinal cancer, and pulmonary disease. [60] [61] Current corticosteroid use is further associated with\u00a0increased mortality. [62]"}
{"id": "article-20133_70", "title": "Crohn Disease -- Complications", "content": "Crohn disease is a systemic\u00a0illness with many intestinal and extraintestinal manifestations. Some of the complications\u00a0associated with this condition are listed below.\u00a0Early detection and treatment adherence can reduce the risk of these complications. Stricture formation Fistulae and abscesses Colorectal carcinoma Ankylosing spondylitis Episcleritis, iritis Erythema nodosum, pyoderma gangrenosum Nephrolithiasis Cholelithiasis Anemia Hypercoagulable state Osteoporosis Osteonecrosis Macro and micronutrient deficiencies Infections", "contents": "Crohn Disease -- Complications. Crohn disease is a systemic\u00a0illness with many intestinal and extraintestinal manifestations. Some of the complications\u00a0associated with this condition are listed below.\u00a0Early detection and treatment adherence can reduce the risk of these complications. Stricture formation Fistulae and abscesses Colorectal carcinoma Ankylosing spondylitis Episcleritis, iritis Erythema nodosum, pyoderma gangrenosum Nephrolithiasis Cholelithiasis Anemia Hypercoagulable state Osteoporosis Osteonecrosis Macro and micronutrient deficiencies Infections"}
{"id": "article-20133_71", "title": "Crohn Disease -- Deterrence and Patient Education", "content": "Preventing Crohn disease is challenging because the exact cause of this condition remains unknown. However, the strategies below may help reduce the risk of developing Crohn disease or mitigate its severity:", "contents": "Crohn Disease -- Deterrence and Patient Education. Preventing Crohn disease is challenging because the exact cause of this condition remains unknown. However, the strategies below may help reduce the risk of developing Crohn disease or mitigate its severity:"}
{"id": "article-20133_72", "title": "Crohn Disease -- Deterrence and Patient Education", "content": "Genetic counseling: Individuals with a family history of Crohn disease may benefit from genetic counseling to understand their risk of developing the condition and discuss potential preventive measures or screening options.", "contents": "Crohn Disease -- Deterrence and Patient Education. Genetic counseling: Individuals with a family history of Crohn disease may benefit from genetic counseling to understand their risk of developing the condition and discuss potential preventive measures or screening options."}
{"id": "article-20133_73", "title": "Crohn Disease -- Deterrence and Patient Education", "content": "Early detection and treatment of symptoms: Being vigilant about recognizing and promptly addressing symptoms suggestive of Crohn disease, such as persistent abdominal pain, diarrhea, rectal bleeding, unexplained weight loss, and fatigue, may help prevent complications and improve long-term outcomes. Seeking medical attention promptly for early signs of Crohn disease is crucial for initiating appropriate treatment and disease management strategies.", "contents": "Crohn Disease -- Deterrence and Patient Education. Early detection and treatment of symptoms: Being vigilant about recognizing and promptly addressing symptoms suggestive of Crohn disease, such as persistent abdominal pain, diarrhea, rectal bleeding, unexplained weight loss, and fatigue, may help prevent complications and improve long-term outcomes. Seeking medical attention promptly for early signs of Crohn disease is crucial for initiating appropriate treatment and disease management strategies."}
{"id": "article-20133_74", "title": "Crohn Disease -- Deterrence and Patient Education", "content": "Dietary modifications: No specific diet has been proven to prevent Crohn disease, but some dietary factors may influence disease risk or exacerbate symptoms in susceptible individuals. Controlling sugar intake and avoiding foods that trigger the symptoms may help prevent flare-ups.", "contents": "Crohn Disease -- Deterrence and Patient Education. Dietary modifications: No specific diet has been proven to prevent Crohn disease, but some dietary factors may influence disease risk or exacerbate symptoms in susceptible individuals. Controlling sugar intake and avoiding foods that trigger the symptoms may help prevent flare-ups."}
{"id": "article-20133_75", "title": "Crohn Disease -- Deterrence and Patient Education", "content": "Avoiding environmental triggers: Environmental factors that may contribute to Crohn disease development or exacerbation and thus must be avoided include cigarette smoke, air pollution, medications like nonsteroidal anti-inflammatory drugs, and infections.", "contents": "Crohn Disease -- Deterrence and Patient Education. Avoiding environmental triggers: Environmental factors that may contribute to Crohn disease development or exacerbation and thus must be avoided include cigarette smoke, air pollution, medications like nonsteroidal anti-inflammatory drugs, and infections."}
{"id": "article-20133_76", "title": "Crohn Disease -- Deterrence and Patient Education", "content": "Secondary prevention consists of measures that help avoid complications after a Crohn disease diagnosis. The following steps may help:", "contents": "Crohn Disease -- Deterrence and Patient Education. Secondary prevention consists of measures that help avoid complications after a Crohn disease diagnosis. The following steps may help:"}
{"id": "article-20133_77", "title": "Crohn Disease -- Deterrence and Patient Education", "content": "Medication adherence: Compliance with prescribed treatment regimens is essential for managing symptoms, reducing inflammation, preventing disease flares, and minimizing the risk of complications. When counseling patients, taking medications as directed, attending regular follow-up appointments, and promptly communicating symptom changes must be emphasized.", "contents": "Crohn Disease -- Deterrence and Patient Education. Medication adherence: Compliance with prescribed treatment regimens is essential for managing symptoms, reducing inflammation, preventing disease flares, and minimizing the risk of complications. When counseling patients, taking medications as directed, attending regular follow-up appointments, and promptly communicating symptom changes must be emphasized."}
{"id": "article-20133_78", "title": "Crohn Disease -- Deterrence and Patient Education", "content": "Cancer screening: Patients with Crohn disease are prone to malignancies, which may include skin and gastrointestinal tumors. Patients should undergo skin cancer screening irrespective of the regimen they received. More frequent screening colonoscopy, ie, every 1 to 3 years, is recommended to detect colon cancer early in patients with inflammation involving at least a third of the colon.", "contents": "Crohn Disease -- Deterrence and Patient Education. Cancer screening: Patients with Crohn disease are prone to malignancies, which may include skin and gastrointestinal tumors. Patients should undergo skin cancer screening irrespective of the regimen they received. More frequent screening colonoscopy, ie, every 1 to 3 years, is recommended to detect colon cancer early in patients with inflammation involving at least a third of the colon."}
{"id": "article-20133_79", "title": "Crohn Disease -- Deterrence and Patient Education", "content": "Osteoporosis prevention: Steroid treatment and Crohn disease\u2013related vitamin deficiencies make patients susceptible to osteoporosis. Bone density should be regularly assessed to allow timely osteoporosis recognition and management.", "contents": "Crohn Disease -- Deterrence and Patient Education. Osteoporosis prevention: Steroid treatment and Crohn disease\u2013related vitamin deficiencies make patients susceptible to osteoporosis. Bone density should be regularly assessed to allow timely osteoporosis recognition and management."}
{"id": "article-20133_80", "title": "Crohn Disease -- Deterrence and Patient Education", "content": "Infection prevention: Immunosuppressive therapy makes patients with Crohn disease vulnerable to infections. Vaccination against lung pathogens, such as pneumococcus, H influenzae , and influenza virus, is recommended. The decision to vaccinate against other microbial agents must be based on patient and geographic factors.", "contents": "Crohn Disease -- Deterrence and Patient Education. Infection prevention: Immunosuppressive therapy makes patients with Crohn disease vulnerable to infections. Vaccination against lung pathogens, such as pneumococcus, H influenzae , and influenza virus, is recommended. The decision to vaccinate against other microbial agents must be based on patient and geographic factors."}
{"id": "article-20133_81", "title": "Crohn Disease -- Deterrence and Patient Education", "content": "Individual responses to these measures may vary, so not all may be applicable or effective for everyone. Further research is needed to better understand the underlying causes of Crohn disease and identify more targeted preventive and treatment approaches.", "contents": "Crohn Disease -- Deterrence and Patient Education. Individual responses to these measures may vary, so not all may be applicable or effective for everyone. Further research is needed to better understand the underlying causes of Crohn disease and identify more targeted preventive and treatment approaches."}
{"id": "article-20133_82", "title": "Crohn Disease -- Enhancing Healthcare Team Outcomes", "content": "Crohn disease is a serious chronic inflammatory disorder that poses various diagnostic and management challenges. This condition's potential to cause multiorgan damage makes an interprofessional care approach imperative. The interprofessional team caring for patients with Crohn disease should include the following:", "contents": "Crohn Disease -- Enhancing Healthcare Team Outcomes. Crohn disease is a serious chronic inflammatory disorder that poses various diagnostic and management challenges. This condition's potential to cause multiorgan damage makes an interprofessional care approach imperative. The interprofessional team caring for patients with Crohn disease should include the following:"}
{"id": "article-20133_83", "title": "Crohn Disease -- Enhancing Healthcare Team Outcomes", "content": "Primary care physicians are usually the first to evaluate patients with mild abdominal complaints, prescribe initial treatment, and refer the patient to specialists for further evaluation and management.", "contents": "Crohn Disease -- Enhancing Healthcare Team Outcomes. Primary care physicians are usually the first to evaluate patients with mild abdominal complaints, prescribe initial treatment, and refer the patient to specialists for further evaluation and management."}
{"id": "article-20133_84", "title": "Crohn Disease -- Enhancing Healthcare Team Outcomes", "content": "Internists may lend expertise in diagnosing recurrent abdominal symptoms associated with systemic manifestations like fever and weight loss. Internists may prescribe additional treatments and refer the patient for further specialized care.", "contents": "Crohn Disease -- Enhancing Healthcare Team Outcomes. Internists may lend expertise in diagnosing recurrent abdominal symptoms associated with systemic manifestations like fever and weight loss. Internists may prescribe additional treatments and refer the patient for further specialized care."}
{"id": "article-20133_85", "title": "Crohn Disease -- Enhancing Healthcare Team Outcomes", "content": "Gastroenterologists are specialists who can perform diagnostic and therapeutic endoscopies, prescribe more targeted therapies, and monitor the disease course.", "contents": "Crohn Disease -- Enhancing Healthcare Team Outcomes. Gastroenterologists are specialists who can perform diagnostic and therapeutic endoscopies, prescribe more targeted therapies, and monitor the disease course."}
{"id": "article-20133_86", "title": "Crohn Disease -- Enhancing Healthcare Team Outcomes", "content": "Colorectal surgeons may be involved if patients present with complications like fistulae and intestinal obstruction.", "contents": "Crohn Disease -- Enhancing Healthcare Team Outcomes. Colorectal surgeons may be involved if patients present with complications like fistulae and intestinal obstruction."}
{"id": "article-20133_87", "title": "Crohn Disease -- Enhancing Healthcare Team Outcomes", "content": "Dietitians educate the patient on the appropriate diet to avoid malnutrition and micronutrient deficiencies.", "contents": "Crohn Disease -- Enhancing Healthcare Team Outcomes. Dietitians educate the patient on the appropriate diet to avoid malnutrition and micronutrient deficiencies."}
{"id": "article-20133_88", "title": "Crohn Disease -- Enhancing Healthcare Team Outcomes", "content": "Nurses: administer treatments, educate the postsurgical patient on treating stomas and surgical wounds, monitor patient progress, and coordinate care.", "contents": "Crohn Disease -- Enhancing Healthcare Team Outcomes. Nurses: administer treatments, educate the postsurgical patient on treating stomas and surgical wounds, monitor patient progress, and coordinate care."}
{"id": "article-20133_89", "title": "Crohn Disease -- Enhancing Healthcare Team Outcomes", "content": "Pharmacists educate the patient regarding their prescribed medical regimens, particularly the benefits, adverse effects, and cruciality of compliance.", "contents": "Crohn Disease -- Enhancing Healthcare Team Outcomes. Pharmacists educate the patient regarding their prescribed medical regimens, particularly the benefits, adverse effects, and cruciality of compliance."}
{"id": "article-20133_90", "title": "Crohn Disease -- Enhancing Healthcare Team Outcomes", "content": "Rheumatologists, neurologists, ophthalmologists, hepatologists, nephrologists, dermatologists, and otorhinolaryngologists are specialists who may be consulted to manage Crohn associated extraintestinal problems.", "contents": "Crohn Disease -- Enhancing Healthcare Team Outcomes. Rheumatologists, neurologists, ophthalmologists, hepatologists, nephrologists, dermatologists, and otorhinolaryngologists are specialists who may be consulted to manage Crohn associated extraintestinal problems."}
{"id": "article-20133_91", "title": "Crohn Disease -- Enhancing Healthcare Team Outcomes", "content": "Mental health providers may lend their expertise to patients who develop depression and severe anxiety due to their symptoms and possible complications.", "contents": "Crohn Disease -- Enhancing Healthcare Team Outcomes. Mental health providers may lend their expertise to patients who develop depression and severe anxiety due to their symptoms and possible complications."}
{"id": "article-20133_92", "title": "Crohn Disease -- Enhancing Healthcare Team Outcomes", "content": "The prognosis for most patients with Crohn disease is guarded, and the quality of life is often poor. [63] An interprofessional team approach can optimize outcomes within the condition's limitations.", "contents": "Crohn Disease -- Enhancing Healthcare Team Outcomes. The prognosis for most patients with Crohn disease is guarded, and the quality of life is often poor. [63] An interprofessional team approach can optimize outcomes within the condition's limitations."}
{"id": "article-20133_93", "title": "Crohn Disease -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Crohn Disease -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}